FDA Says Jemperli May Let Some Rectal Cancer Patients Avoid Surgery, Chemo and Radiation
The agency granted accelerated approval to GSK's immunotherapy for adults with untreated stage II or III rectal cancer whose tumors are dMMR or MSI-H, based on interim trial results. Longer follow-up is still required.
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
The Food and Drug Administration on Monday, Oct. 19, granted accelerated approval to GSK's immunotherapy Jemperli for adults with stage II or stage III locally…
More reporting and context continue here.
The complete story is available with Premium.
Read the facts, open questions and supporting sources.
Continue reading with NewsPlain Premium.
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.